thumbnail image
  • AmDTx
  • SCIENCE
  • CLINICAL TRIALS
  • PARTNERS 
    • PHARMA
    • PAYORS
    • HEALTH SYSTEMS
  • NEWS
  • MEET THE TEAM 
    • FULL TEAM
    • CHIEF EXECUTIVE OFFICER
    • CHIEF TECHNOLOGY OFFICER
    • CHIEF FINANCIAL OFFICER
    • CHIEF OF CONTENT
    • VP PHARMACEUTICALS
    • ASSISTANT TO THE CEO
    • CAREERS
  • …  
    • AmDTx
    • SCIENCE
    • CLINICAL TRIALS
    • PARTNERS 
      • PHARMA
      • PAYORS
      • HEALTH SYSTEMS
    • NEWS
    • MEET THE TEAM 
      • FULL TEAM
      • CHIEF EXECUTIVE OFFICER
      • CHIEF TECHNOLOGY OFFICER
      • CHIEF FINANCIAL OFFICER
      • CHIEF OF CONTENT
      • VP PHARMACEUTICALS
      • ASSISTANT TO THE CEO
      • CAREERS
    • AmDTx
    • SCIENCE
    • CLINICAL TRIALS
    • PARTNERS 
      • PHARMA
      • PAYORS
      • HEALTH SYSTEMS
    • NEWS
    • MEET THE TEAM 
      • FULL TEAM
      • CHIEF EXECUTIVE OFFICER
      • CHIEF TECHNOLOGY OFFICER
      • CHIEF FINANCIAL OFFICER
      • CHIEF OF CONTENT
      • VP PHARMACEUTICALS
      • ASSISTANT TO THE CEO
      • CAREERS
    • …  
      • AmDTx
      • SCIENCE
      • CLINICAL TRIALS
      • PARTNERS 
        • PHARMA
        • PAYORS
        • HEALTH SYSTEMS
      • NEWS
      • MEET THE TEAM 
        • FULL TEAM
        • CHIEF EXECUTIVE OFFICER
        • CHIEF TECHNOLOGY OFFICER
        • CHIEF FINANCIAL OFFICER
        • CHIEF OF CONTENT
        • VP PHARMACEUTICALS
        • ASSISTANT TO THE CEO
        • CAREERS
      • Personalised mental healthcare at scale.

         

        Discover what makes Mobio Interactive unique.

        PRE-A DECK
      • News video: Groundbreaking new treatments for concussion
      • Problem

        It is exceptionally difficult to deliver precision psychiatry at scale.

        Solution

        MI combines computer vision, AI and clinically validate psychotherapy, in a single, easy-to-use mobile platform.

        Product: AmDTx, precision psychiatry at scale

        Personalisation of mental healthcare via real time measurement of therapy efficacy with a validated digital biomarker of stress.

         

        This solution is 100% MI IP, scales and integrates seamlessly into clinicians’ pre-existing workflows.

        Business Model

        Platform licensing to hospitals and payors establishes the critical infrastructure and ease of use that supports rapid prescription and adoption of regulated Class II SaMD interventions.

        Competitive Advantages

        • World’s most accurate objective quantification of stress from mobile selfie video (>80% accuracy*)
        • >2.5 million digital biomarkers data points from >25k individuals from 175 countries.
        • Clinically validated therapy

        *Al-Jebrni et al., AI-enabled remote and objective quantification of stress at scale. BSPC 2020

        Traction

        • Established clients across three target verticals: Health Systems, Payors, Pharma
        • FDA Breakthrough Device Designation pending
        • Respected institutional investors

        Opportunity & Impact

        MI is rapidly approaching its next inflection point: FDA clearance. When this comes to pass, valuation will increase and new capital will be raised. Pre A investors guarantee FDA clearance.

        Globally, more than 1 in 10 people need mental health therapy. Digital therapies for mental illness will reach $500 billion/yr by 2035. As an early leader, MI aims to capture 10% of this market opportunity as the first in history to achieve precision psychiatry at scale.

      CONTACT US

      TERMS OF USE

      PRIVACY POLICY

      Effective and accessible healthcare for every human.

        Cookie Use
        We use cookies to ensure a smooth browsing experience. By continuing we assume you accept the use of cookies.
        Learn More